5102-LID
Total Payments
$386,503
Transactions
65
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $386,503 | 65 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $386,503 | 65 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| OPEN-LABEL SAFETY STUDY OF ADS-5102 AMANTADINE HCL EXTENDED RELEASE CAPSULES FOR THE TREATMENT OF LEVODOPA INDUCED DYSKINESIA | Adamas Pharmaceuticals, Inc. | $368,831 | 0 |
| A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT | Adamas Pharmaceuticals, Inc. | $7,709 | 0 |
| OPEN-LABEL SAFETY STUDY OF ADS-5102 (AMANTADINE HCL) EXTENDED RELEASE CAPSULES FOR THE TREATMENT OF LEVODOPA INDUCED DYSKINESIA | Adamas Pharmaceuticals, Inc. | $6,463 | 0 |
| EFFICACY AND SAFETY OF ADS-5102 AMANTADINE HCL EXTENDED RELEASE CAPSULES FOR THE TREATMENT OF LEVODOPA INDUCED DYSKINESIA IN PARKINSONS DISEASE PATIENTS EASE LID STUDY | Adamas Pharmaceuticals, Inc. | $3,500 | 0 |
Top Doctors Receiving Payments for 5102-LID
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $386,503 | 65 |
Ad
Manufacturing Companies
- Adamas Pharmaceuticals, Inc. $386,503
Product Information
- Type Drug
- Total Payments $386,503
- Total Doctors 0
- Transactions 65
About 5102-LID
5102-LID is a drug associated with $386,503 in payments to 0 healthcare providers, recorded across 65 transactions in the CMS Open Payments database. The primary manufacturer is Adamas Pharmaceuticals, Inc..
Payment data is available from 2018 to 2018. In 2018, $386,503 was paid across 65 transactions to 0 doctors.
The most common payment nature for 5102-LID is "Unspecified" ($386,503, 100.0% of total).
5102-LID is associated with 4 research studies, including "OPEN-LABEL SAFETY STUDY OF ADS-5102 AMANTADINE HCL EXTENDED RELEASE CAPSULES FOR THE TREATMENT OF LEVODOPA INDUCED DYSKINESIA" ($368,831).